Zetagen Therapeutics develops ZetaMet™ (Zeta-BC-003), a small molecule therapy that targets metastatic bone lesions by suspending cancer, inhibiting pain, and regenerating bone. This therapy aims to improve survival rates for patients with metastatic breast cancer through localized administration, demonstrating significant reductions in tumor burden and pain in pre-clinical studies.
Funding
$9.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CINYFounders
Product
Problem
Metastatic bone lesions, particularly from breast and prostate cancer, cause significant pain, increase the risk of fractures, and reduce the overall quality of life for patients. Current standard of care treatments like radiation therapy offer limited pain relief and have not been shown to prevent fractures, resulting in a poor median survival rate following skeletal-related events.
Solution
Zetagen Therapeutics is developing a suite of locally administered therapies designed to target and resolve metastatic cancer lesions in bone and soft tissue. Their lead candidate, ZetaMet™ (Zeta-BC-003), is a small-molecule therapy delivered via a proprietary controlled-release carrier, designed to resolve bone lesions, inhibit pain, and stimulate targeted bone regeneration. ZetaMAST™ (Zeta-MBC-005) is being developed for unresectable, multifocal breast cancer metastases to the liver, lung, or brain, administered as a percutaneous injection utilizing a proprietary hydrogel carrier. Zetagen's therapies aim to improve patient outcomes by directly addressing the osteolysis and pain associated with metastatic disease, with the potential to increase survival rates.
Target Audience
The primary target audience includes oncologists and patients with metastatic cancers, specifically breast and prostate cancer, who are experiencing bone lesions and associated pain.
Features
- ZetaMet™ (Zeta-BC-003): Synthetic small molecule therapy for metastatic bone lesions, currently in Phase 2a clinical trials for metastatic breast cancer to the spine.
- ZetaMAST™ (Zeta-MBC-005): Novel drug for unresectable, multifocal breast cancer metastases, delivered via percutaneous injection with a hydrogel carrier.
- ZetaMet-P™ (Zeta-PC-004): Small-molecule antitumorigenic therapy being developed to target and resolve metastatic prostate cancer bone lesions.
- ZetaBase®: Osteo-conductive and osteo-promotive carrier for ZetaMet™, formulated to aid bone healing in the treatment of metastatic lytic bone lesions; can also be used as a bone void filler.
- Local administration: Therapies are designed for local administration to bone or soft tissue organs, potentially minimizing systemic side effects.
- Breakthrough Designation: ZetaMet™ (Zeta-BC-003) has received Breakthrough Designation from the FDA for the treatment of metastatic bone cancer.